Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma.

Satoshi Moriya(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Akito Nozaki(Yokohama City University Medical Center), Masaaki Kondo(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Shin Maeda(University of Tokyo Hospital), Masayuki Nakano(Nihon University), Yu Shimoyama
PubMed
March 1, 2013
Cited by 25

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333